Mosunetuzumab Monotherapy Demonstrates Durable Efficacy With a Manageable Safety Profile in Patients With Relapsed/Refractory Follicular Lymphoma who Received ≥2 Prior Therapies: Updated Results From a Pivotal Phase II Study

被引：0

作者：

Bartlett, Nancy L. ^{[1
]}

Sehn, Laurie H. ^{[2
,3
]}

Matasar, Matthew ^{[4
]}

Schuster, Stephen J. ^{[5
]}

Assouline, Sarit ^{[6
]}

Giri, Pratyush ^{[7
]}

Kuruvilla, John ^{[8
]}

Canales, Miguel ^{[9
]}

Dietrich, Sascha ^{[10
]}

Fay, Keith ^{[11
,12
]}

Ku, Matthew ^{[13
]}

Nastoupil, Loretta ^{[14
]}

Wei, Michael C. ^{[15
]}

Yin, Shen ^{[15
]}

To, Iris ^{[15
]}

Huang, Huang ^{[16
]}

Min, Juliana ^{[17
]}

Bolen, Christopher R. ^{[15
]}

Penuel, Elicia ^{[15
]}

Budde, L. Elizabeth ^{[18
]}

机构：

[1] Washington Univ, Siteman Canc Ctr, Sch Med, St Louis, MO USA

[2] BC Canc Ctr Lymphoid Canc, Vancouver, BC, Canada

[3] Univ British Columbia, Vancouver, BC, Canada

[4] Mem Sloan Kettering Canc Ctr, New York, NY USA

[5] Univ Penn, Lymphoma Program, Abramson Canc Ctr, Philadelphia, PA USA

[6] McGill Univ, Jewish Gen Hosp, Montreal, PQ, Canada

[7] Royal Adelaide Hosp, Adelaide, SA, Australia

[8] Princess Margaret Canc Ctr, Toronto, ON, Canada

[9] Hosp Univ La Paz, Madrid, Spain

[10] Heidelberg Univ, Heidelberg, Germany

[11] St Vincents Hosp, Sydney, NSW, Australia

[12] Royal North Shore Hosp, Sydney, NSW, Australia

[13] Univ Melbourne, St Vincents Hosp, Melbourne, Australia

[14] MD Anderson Canc Ctr, Houston, TX USA

[15] Genentech Inc, San Francisco, CA USA

[16] Hoffmann La Roche Ltd, Mississauga, ON, Canada

[17] Roche Prod Ltd, Welwyn Garden City, Herts, England

[18] City Hope Natl Med Ctr, Duarte, CA USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

IBCL; mosunetuzumab; bispecific antibody; relapsed/refractory; follicular lymphoma; Phase II;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

IBCL-458

引用

页码：S453 / S453

页数：1

共 12 条

[1] Mosunetuzumab Monotherapy Continues to Demonstrate Durable Responses in Patients With Relapsed and/or Refractory Follicular Lymphoma After=2 Prior Therapies: 3-Year Follow-Up From a Pivotal Phase II Study
Schuster, Stephen J.
Sehn, Laurie H.
Bartlett, Nancy L.
Matasar, Matthew
Assouline, Sarit
Giri, Pratyush
Kuruvilla, John
Shadman, Mazyar
Cheah, Chan Y.
Dietrich, Sascha
Fay, Keith
Ku, Matthew
Nastoupil, Loretta
Wei, Michael C.
Yin, Shen
To, Iris
Huang, Jiangeng
Kwan, Antonia
Penuel, Elicia
Budde, L. Elizabeth
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S497 - S497
[2] Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients With Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received.2 Prior Lines of Therapy: Pivotal Results From a Phase I/II Study
Budde, Elizabeth L.
Sehn, Laurie H.
Matasar, Matthew
Schuster, Stephen J.
Assouline, Sarit
Giri, Pratyush
Kuruvilla, John
Canales, Miguel
Dietrich, Sascha
Fay, Keith
Ku, Matthew
Nastoupil, Loretta
Wei, Michael C.
Yin, Shen
Doral, Michelle Y.
Li, Chi-Chung
Huang, Huang
Negricea, Raluca
Penuel, Elicia
O'Hear, Carol
Bartlett, Nancy L.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S387 - S387
[3] Glofitamab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma and ≥2 Prior Therapies: Results From a Pivotal Phase II Expansion Study
Dickinson, Michael
Carlo-Stella, Carmelo
Morschhauser, Franck
Bachy, Emmanuel
Corradini, Paolo
Iacoboni, Gloria
Khan, Cyrus
Wrobel, Thomasz
Offner, Fritz
Trneny, Marek
Wu, Shang-Ju
Cartron, Guillaume
Hertzberg, Mark
Sureda, Anna
Perez-Callejo, David
Lundberg, Linda
Relf, James
Clark, Emma
Humphrey, Kathryn
Hutchings, Martin
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S435 - S435
[4] Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience From a Pivotal Phase I/II Trial
Matasar, Matthew
Bartlett, Nancy L.
Shadman, Mazyar
Budde, Lihua E.
Flinn, Ian
Gregory, Gareth P.
Kim, Won Seog
Hess, Georg
El-Sharkawi, Dima
Diefenbach, Catherine S.
Huang, Huang
To, Iris
Parreira, Joana
Wu, Mei
Kwan, Antonia
Assouline, Sarit
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (04) : 240 - 253
[5] Primary Efficacy and Safety Analysis of a Global Phase II Study of Zandelisib Administered by Intermittent Dosing (ID) in Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL): The TIDAL Study
Phillips, Tycel
Jurczak, Wojciech
Ribrag, Vincent
Linton, Kim
Collin, Graham P.
Lopez-Jimenez, Javier
Reddy, Nishitha
Mengarelli, Andrea
Musuraca, Gerardo
Sheehy, Oonagh
Xu, Weiming
Azoulay, Michel
Ghalie, Richard G.
Zinzani, Pier Luigi
Zelenetz, Andrew D.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S387 - S388
[6] Glofitamab Monotherapy In Patients With Heavily Pretreated Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Updated Analysis From A Phase 1/2 Study
Phillips, Tycel
Carlo-Stella, Carmelo
Morschhauser, Franck
Bachy, Emmanuel
Crump, Michael
Trneny, Marek
Bartlett, Nancy L.
Zaucha, Jan
Wrobel, Tomasz
Offner, Fritz
de L'Etang, Audrey Filezac
Relf, James
Carlile, David J.
Byrne, Ben
Mulvihill, Estefania
Lundberg, Linda
Dickinson, Michael
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S515 - S516
[7] Subcutaneous Epcoritamab in Patients With Relapsed or Refractory Large B-Cell Lymphoma (EPCORE NHL-1): Pivotal Results from a Phase 2 Study
Thieblemont, Catherine
Phillips, Tycel
Ghesquieres, Herve
Cheah, Chan Y.
Clausen, Michael Roost
Cunningham, David
Do, Young Rok
Feldman, Tatyana
Gasiorowski, Robin
Jurczak, Wojciech
Kim, Tae Min
Lewis, David John
van der Poel, Marjolein
Poon, Michelle Limei
Doerr, Thomas
Kilavuz, Nurgul
Chen, Menghui
Sacchi, Mariana
Elliott, Brian
Hutchings, Martin
Lugtenburg, Pieternella
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S379 - S379
[8] Promising Tolerability and Efficacy Results from Dose-Escalation in an Ongoing Phase Ib/II Study of Mosunetuzumab with Polatuzumab Vedotin (Pola) in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)
Budde, Elizabeth
Ghosh, Nilanjan
Chavez, Julio
Lossos, Izidore S.
Mehta, Amitkumar
Dorritie, Kathleen
Kamdar, Manali
Negricea, Raluca
Song Pham
Hristopoulos, Maria
Huw, Ling-Yuh
O'Hear, Carol
Oki, Yasuhiro
To, Iris
Diefenbach, Catherine
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S393 - S394
[9] Nivolumab Combined with Brentuximab Vedotin (BV) for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma (R/R PMBL): Efficacy and Safety Results from the Phase 2 CheckMate 436 Study
Zinzani, Pier Luigi
Santoro, Armando
Gritti, Guiseppe
Brice, Pauline
Barr, Paul M.
Kuruvilla, John
Cunningham, David
Kline, Justin
Johnson, Nathalie A.
Mehta-Shah, Neha A.
Manley, Thomas
Francis, Stephen
Sharma, Manish
Moskowitz, Alison J.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S303 - S303
[10] Talquetamab (Tal), a GPRC5DxCD3 Bispecific Antibody (BsAb), in Combination With Pomalidomide (Pom) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Efficacy and Safety Results From the Phase 1b MonumenTAL-2 Study
Searle, Emma
Quach, Hang
Biran, Noa
Perrot, Aurore
Berdeja, Jesus G.
Dorritie, Kathleen
Van Elssen, Catharina
Touzeau, Cyrille
Anguille, Sebastien
Vishwamitra, Deeksha
Nguyen, Ashley
Ghosh, Debopriya
Shearin, Elizabeth
Mason, Gary E.
Renaud, Thomas
Matous, Jeffrey
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S549 - S550

← 1 2 →